



Express Mail No. EV 456 933 477 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jeannette Whitcomb Confirmation No.: To be assigned

Serial No.: 10/758,683 Art Unit: 1648

Filed: January 14, 2004 Examiner: To be assigned

For: MEANS AND METHODS FOR Attorney Docket No: 11068-078-999
MONITORING NON-NUCLEOSIDE
REVERSE TRANSCRIPTASE
INHIBITOR ANTIRETROVIRAL
THERAPY AND GUIDING
THERAPEUTIC DECISIONS IN THE
TREATMENT OF HIV/AIDS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:
 - 1a. ☒ A list of all patents, publications, applications, or other information submitted for consideration by the office.
 - 1b. A legible copy of :
 - ☒ Each U.S. patent application publication and U.S. and foreign patent;
 - ☒ Each publication or that portion which caused it to be listed on the PTO-1449;
 - ☐ For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;
 - ☐ all other information or portion which caused it to be listed on the PTO-1449.
 - 1c. ☒ An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.
 - 1d. ☐ Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.
2. ☒ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):
 - ☐ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);

- ☐ Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
- ☒ Before the mailing of the first Office action on the merits;
- ☐ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.

3. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

(Check either Item 3a or 3b)

- 3a. ☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b. ☐ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
- ☐ enclosed
 - ☐ to be charged to Jones Day Deposit Account No. 50-3013.

(Item 3b to be checked if any reference known for more than 3 months)

4. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:

- ☐ enclosed.
- ☐ to be charged to Jones Day Deposit Account No. 50-3013.

The Certification Statement in Item 5 below is applicable.

5. ☐ Certification Statement (applicable if Item 3a or Item 4 is checked)

(Check either Item 5a or 5b)

- 5a. ☐ In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- 5b. ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- 5c. ☐ Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.


6. ☐ This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).

(Check appropriate Items 6a, 6b and/or 6c)

- 6a. ☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
- 6b. ☐ Copies of publications listed on Form PTO-1449 from prior application Serial No. 09/881,033, filed on June 12, 2001, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
- 6c. ☐ Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.
7. ☐ This is a Supplemental Information Disclosure Statement. (Check Item 7a)
- 7a. ☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .
8. ☐ In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:
- (Check Item 8a, 8b, or 8c)
- 8a. ☐ satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
- 8b. ☐ set forth in the application.
- 8c. ☐ enclosed as an attachment hereto.
9. ☒ The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to to be charged to Jones Day Deposit Account No. 50-3013.
10. ☒ No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).


Respectfully submitted,

Date: July 7, 2004


David Pauling for
Nikolaos C. George (Reg. No. 39,201)
JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

56,056

(Reg. No.)

 <p>LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)</p>	ATTY DOCKET NO. 11068-078-999	APPLICATION NO 10/758,683
	APPLICANT Whitcomb, Jeannette	
	FILING DATE January 14, 2004	GROUP 1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	5,436,131	7/95	Condra <i>et al.</i>			
	A02	5,631,128	5/97	Kozal <i>et al.</i>			
	A03	5,650,268	7/97	Kozal <i>et al.</i>			
	A04	5,837,464	11/98	Capon <i>et al.</i>			
	A05	5,917,033	6/99	Modak <i>et al.</i>			
	A06	6,033,902	3/00	Haseltine <i>et al.</i>			
	A07	6,103,462	8/00	Paulous <i>et al.</i>			
	A08	6,124,327	9/00	Silverman			
	A09	6,242,187	6/01	Capon <i>et al.</i>			
	A10	6,653,081	11/03	Whitcomb			
	A11	20040067487	4/04	Whitcomb			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A12	WO99/67427	6/99	PCT				
	A13	WO99/61658	12/99	PCT				
	A14	WO02/22781	9/01	PCT				
	A15	International Search Report of PCT/US99/14486	6/99	PCT				
	A16	International Search Report of PCT/US01/28736	5/02	PCT				
	A17	International Search Report of PCT/US99/11629	9/99	PCT				
	A18	International Search Report of PCT/US01/18882	10/01	PCT				
	A19	Copy of International Search Report PCT/US03/21024	5/04	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	A20	Ahluwalia, G. S., <i>et al.</i> (1996) "2', 3'-Didehydro-3 ¹ -deoxythymidine: Regulation of its Metabolic Activation by Modulators of Thymidine-5'-triphosphate Biosynthesis" <i>Mol. Pharm.</i> 50: 160-165
	A21	Appelt, <i>et al.</i> , (1991) "Design of Enzyme Inhibitors Using Iterative Protein Crystallographic Analysis," <i>J. Med. Chem.</i> 34: 1925-1934.
	A22	Arnold E., <i>et al.</i> (1995) "Structures of DNA and RNA Polymerases and Their Interactions with Nucleic Acid Substrates", <i>Curr Opin Struct Biol</i> 5:27-38;

A23	Back, KT, et al, (1996) "Reduce Replication of 3TC-Resistant HIV-1 Variants in Primary Cells Due to a Processivity Defect of the Reverse Transcriptase Enzyme", <i>EMBO</i> 15: 4040-4049
A24	Balzarini J, (1998) "A Novel Mutation (F227L) Arises in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 on Dose-Escalating Treatment of HIV Type 1-Infected Cell Cultures With the Nucleoside Reverse Transcriptase Inhibitor Thiocarboxanilide UC-781" <i>AIDS Res. Human</i> , 14(3):255-260
A25	Balzarini J, et al. (1997) "Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Strains Subcultured in the of Both Lamivudine and Quinoxaline HBY 097 Retain Marked Sensitivity to HBY 097 but not to Lamivudine" <i>J of Infect Dis</i> , 176:1392-1397
A26	Balzarini J., et al., (1992) "HIV-1-Specific Reverse Transcriptase Inhibitors Show Differential Activity Against HIV1 Mutant Strains Containing Different Amino Acid Substitutions in the Reverse Transcriptase", <i>Virology</i> 192:246-253
A27	Barnes WM, (1994) "PCR Amplification of up to 35-kb DNA with High Fidelity and High Yield from <i>λ</i> Bacteriophage Templates" <i>PNAS</i> 91:2216-2220
A28	Bartenschlager R, et al, (1994) "Kinetic and Structural Analyses of Hepatitis C Virus Polyprotein Processing", <i>J. Virol.</i> 68:5045-5055
A29	Boucher CAB, et al, (1993) "High-Level Resistance to (-) Enantiomeric 2'-Deoxy-3'-Thiacytidine In Vitro is Due to One Amino Acid Substitution in the Catalytic Site of Human Immunodeficiency Virus Type 1 Reverse Transcriptase", <i>Antimicrob Agents Chemother</i> , 37:2231-2234
A30	Boucher CAB, et al, (1990) "Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy", <i>Lancet</i> 336:585-590
A31	Boyer, et al., "Analysis of Nucleoside Drug-Resistant Variants of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <i>J. Virol.</i> , 67(4):2412-2420 (1993).
A32	Cheeseman S.H., et al. (1995) "Phase I/II Evaluation of Defic Nevirapine Alone and in Combination with Zidovudine for Infection with Human Immunodeficiency Virus", <i>J Acquir Immune Syndr</i> 8:141-151
A33	Coffin JM, (1995) "HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy", <i>Science</i> 267:483-489
A34	Craig C and Moyle G, (1997) "The development of resistance of HIV-1 to zalcitabine", <i>AIDS</i> 11:271-279.
A35	Croteau G. et al (1997) "Impaired Fitness of Human Immunodeficiency Virus Type 1 Variants with High-Level Resistance to Protease Inhibitors" <i>J Virol</i> 71:1089-1096
A36	D'Aquila R.T. (1994) "Molecular Pathogenesis and Laboratory Monitoring", <i>Clin Lab Med</i> 14:393-423
A37	De Clercq E, (1997) "Development of Resistance of Human the 4); Immunodeficiency Virus (HIV) to Anti-HIV Agents: How to Prevent Problem" <i>Intl of Antimicro Agnts</i> , 9:21-36
A38	De Clercq E, (1992) "HIV Inhibitors Targeted at the Reverse Transcriptase", <i>AIDS Res. Hum Retrovin.</i> 8:119-134
A39	DeJong, M.D., et al. (1994) "Alternating Nevirapine and Infected Zidovudine Treatment of Human Immunodeficiency Virus Type 1Persons Does Not Prolong Nevirapine Activity", <i>J Infect Dis</i> 169:1346-1350
A40	DeJong MD, et al, (1996) "Host-parasite Dynamics and Outgrowth of Virus Containing a Single K7OR Amino Acid Change in Reverse Transcriptase are Responsible for the Loss of Human Immunodeficiency Virus Type 1 RNA Load Suppression by Zidovudine", <i>PNAS</i> 93:5501-5506
A41	Descamps, et al., 1997 "Susceptibility of Human Immunodeficiency Virus Type 1 Group O Isolates to Antiretroviral Agents: In Vitro Phenotypic and Genotypic Analysis," <i>J. of Virology</i> 71(11): 8893-98.
A42	De Antoni A., et al. Mutations in a pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. <i>J. Infect Dis.</i> (1997) OCT.; 176(4): 899-903
A43	Doyon L, et al, (1996) "Second Locus Involved in Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors", <i>J Virol</i> 70:3763-3769
A44	Dueweke, T.J., et al. (1993) "A Mutation in Reverse to Other Transcriptase of Bis (Heteroaryl) Piperazine Resistant Human Immunodeficiency Virus Type 1. That Confers Increased Sensitivity; Nucleoside Inhibitors", <i>PNAS</i> 90:4713-4717
A45	Eastman, P. Scott, et al. (1995) Monisotopic Hybridization Assay for Determination of Relative Amounts of Genotypic Human Micro, Immunodeficiency Virus Type 1 Zidovudine Resistance", <i>J Clin</i> 2777-2780
A46	Fitzgibbon et al. Human Immunodeficiency virus type 1 pol gene mutations in an AIDS pateint treated with multiple antiretroviral drugs. <i>Journal of Virology</i> , vol. 67, No. 12 (1993) pp. 7271-7275.
A47	Frenkel et al. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. <i>Journal of Clinical Immunology</i> . vol. 33, No. 2 (1995) pp. 342-347.
A48	Frost, S.D.W., and McLean, A.R. (1994) "Quasispecies Dynamics and the Emergence of Drug Resistance During Zidovudine Therapy of Hiv Infection", <i>AIDS</i> 8:323-332.
A49	Gerondelis P, et al, (1999) "The P236L Delavirdine-Resistant Human Immunodeficiency Virus Type 1 Mutant is Replication Defective and Demonstrates Alternations in both RNA 5'-End-and DNA 3',-End-Directed Rnase H Activities", <i>J Virol.</i> 73: 5803-5813
A50	Gervaix, et al., "A New Reporter Cell Line to Monitor HIV Infection and Drug Susceptibility in Vitro", <i>Proc. Natl. Acad. Sci. USA</i> (1997), Vol. 94 pgs 4653-4658.

A51	Goulden MG, et al, (1996) "Selection In Vitro of an HIV-1 Variant Resistant to Both Lamivudine (3TC) and Zidovudine", <i>AIDS</i> 10:101-102.
A52	Gu Z, et al, (1994) "Identification of Novel Mutations that Confer Drug Resistance In the Human Immunodeficiency Virus Polymerase Gene", <i>Leukemia</i> 8(1):166-169.
A53	Hammond, <i>et al.</i> , 1998 "Mutations in Retroviral Genes Associated with Drug Resistance," 36-79.
A54	Harrigan PR, et al, (1998) "Relative Replication Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro", <i>J Virol.</i> 72:3773-3778
A55	Ho DD, et al, (1994) "Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to a C2-Symmetric Protease Inhibitor", <i>J Virol</i> 68:2016-2020
A56	Holodniy, Mark, <i>et al.</i> (1995) "Determination of Human Immunodeficiency Virus RNA In Plasma and Cellular Viral DNA Genotypic Zidovudine Resistance Combination Therapy", <i>J Virol.</i> 3510-3516
A57	Hazuda, <i>et al.</i> , 2000 "Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells," <i>Science</i> 287: 646-650.
A58	Herrmann, <i>et al.</i> , "A Working Hypotheses-Virus Resistance Development As An Indicator of Specific Antiviral Activity", <i>Ann. NY Acad Sciences</i> (1997), 284: 632-637.
A59	Hertogs, <i>et al.</i> , "A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates From Patients Treated with Antiretroviral Drugs", <i>Antimicrobial Agents and Chemotherapy</i> (1998) 42(2): 269-276.
A60	Iversen <i>et al.</i> "Multidrug-resistant immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy," <i>Journal of Virology.</i> vol. 70, No. 2 (1996) pp. 1086-1090.
A61	Kellam, P., <i>et al.</i> (1994) "Zidovudine Treatment Results in the Selection of Human Immunodeficiency Virus Type 1 Variants Whose Genotypes Confer Increasing Levels of Drug Resistance", <i>J Gen Virol</i> 75:341-351.
A62	Kim EE, et al, (1995) "Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme", <i>J Am Chem Soc.</i> 117: 1181-1182
A63	Kleim, J., <i>et al.</i> (1997) "In vitro Selection for Different Mutational Patterns in the HIV-1 Reverse Transcriptase Using High and Low Selective Pressure of the Nucleoside Reverse Transcriptase inhibitor HBV 097" <i>Virology.</i> 231: 112-118
A64	Kosalaraksa P, et al, (1999) "Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay", <i>J Virol</i> 73:5356-5363.
A65	Krebs, R., <i>et al.</i> 1997 "Single-Step Kinetics of HIV-1 Reverse Transcriptase Mutants Responsible for Virus Resistance to Nucleoside Inhibitors Responsible for Virus Resistance to Nucleoside Inhibitors Zidovudine and 3-TC" <i>Biochemistry</i> 36: 10292-10300
A66	Kuritzkes D.R. Clinical significance of drug resistance in HIV-1 infection. <i>AIDS</i> (1996) vol. 10, S27-S31.
A67	Larder BA, (1992) "3'-Azido-3'-Deoxythymidine Resistance Suppressed by a Mutation Conferring Human Immunodeficiency Virus Type 1 Resistance to Nucleoside Reverse Transcriptase Inhibitors", <i>Antimicrob Agents Chemother</i> 36: 2664-2669.
A68	Larder BA, et al, (1991) "Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes", <i>AIDS</i> 5:137-144.
A69	Larder BA, et al, (1995) "Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy", <i>Science</i> 269:696-699.
A70	Lie, <i>et al.</i> , "Advances In Quantitative PCR Technology: 5' Nuclease Assays", <i>Curr Opin Biotech</i> (1998), 9(1): 43-48.
A71	Lieven Stuyver, <i>et al.</i> (1997) "Line Probe Assay For Rapid Detection Of Drug Selected Mutations In The Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene", <i>Antimicrob Agents and Chemother.</i> 284-291
A72	Lin PF, et al, (1994) "Genotypic and Phenotypic Analysis of Human Immunodeficiency Virus Type 1 Isolates from Patients on Prolonged Stavudine Therapy", <i>J Infect Disease</i> 170:1157-1164.
A73	Lopez-Galindez C, et al, (1991) "Characterization of genetic variation and 3'-azido-3'-deoxythymidine-resistance mutations of human immunodeficiency virus by the RNAase A mismatch cleavage method", <i>PNAS</i> 88:4280-4284.
A74	Mammamo F, et al, (1998) "Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease and gag Coevolution in Protease Inhibitor-Treated Patients", <i>J Virol</i> 72:7632-7637
A75	Maschera B, et al, (1996) "Mutations in the Viral Protease that Confer Resistance to Saquinavir Increase the Dissociation Rate Constant of the Protease-Saquinavir Complex", <i>Bio Chem</i> 271:33231-33235.
A76	Mayers DL, et al, (1992) "Characterization of HIV Isolates Arising After Prolonged Zidovudine Therapy", <i>J Acq Imm Def Synd</i> 5:749-759
A77	Moyle GJ (1996) "Use of Viral Resistance Patterns to Antiretroviral Drugs in Optimizing Selection of Drug Combinations and Sequences", <i>Drugs</i> 52:168-185
A78	Mohri, H., <i>et al.</i> (1993) "Quantitation of Zidovudine Resistant Human Immunodeficiency Virus Type 1 in the Blood of Treated and Untreated Patients", <i>PNAS</i> 90:25-29

A79	Mulligan RC and Berg P, (1980) "Expression of a Bacterial Gene in Mammalian Cells", <i>Science</i> 209:1422-11427
A80	Nájera, I., <i>et al.</i> (1994) "Natural Occurrence of Drug Resistance Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Isolates", <i>Aids Res Hum Retroviruses</i> 10:1479-1488
A81	Nájera, I., <i>et al.</i> (1995) "pol Gene Quasispecies of Human Immunodeficiency Virus: Mutations Associated with Drug Resistance in virus from Patients Undergoing No Drug Therapy", <i>J Virol</i> 69:23-31
A82	Nijhuis, <i>et al.</i> , "Implications of Antiretroviral Resistance on Viral Fitness", <i>Curr. Opin. Infect Diseases</i> (2001), 14: 23-28.
A83	Nunberg, J.H., <i>et al.</i> (1990) "Viral Resistance to Human Immunodeficiency Virus Type 1-Specific Pyridinone Reverse Transcriptase Inhibitors", <i>J Virol</i> 65:4887-4892
A84	Pelemans H, <i>et al.</i> (1997) "Characteristics of the Pro225His Mutation in Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase That Appears Under Selective Pressure of Dose Escalating Quinoxaline Treatment of HIV-1" <i>J. Virol.</i> , 71(11) :8195-8203
A85	Petropoulos, <i>et al.</i> , "A Novel Phenotypic Drug Susceptibility Assay For Human Immunodeficiency Virus Type 1", <i>Antimicrobial Agents and Chemotherapy</i> (2000), 44(4): 920-928.
A86	Race, <i>et al.</i> , "Analysis of HIV Cross-Resistance to Protease Inhibitors Using A Rapid Single-Cycle Recombinant Virus Assay For Patients Failing On Combination Therapies", <i>AIDS</i> (1999), 13(15): 2061-2068.
A87	Richman, D.D. <i>et al.</i> (1994) "Nevirapine Resistance Mutations of Human Immunodeficiency Virus Type 1 Selected during Therapy", <i>J Virol</i> 68:1660-1666
A88	Richman, D.D. <i>et al.</i> (1991) "Human Immunodeficiency Virus Type 1 Mutants Resistant to Nonnucleoside Inhibitors of Reverse Transcriptase Arise in Tissue Culture", <i>PNAS</i> 88:11241-11245
A89	Sanger, <i>et al.</i> (1977) "DNA Sequencing with Chain-terminating Inhibitors", <i>PNAS</i> 88: 11241-245.
A90	Sakar, G. and Sommer, S.S. (1990) "The "Megaprimer" Method of Site-Directed Mutagenesis" <i>Biotech</i> , 8(4):404-407
A91	Sanger, <i>et al.</i> (1977) "DNA Sequencing with Chain-terminating Inhibitors", <i>PNAS</i> 88: 11241-245.
A92	Shafer RW, <i>et al.</i> (1994) "Combination Therapy with Zidovudine and Didanosine Selects for Drug-Resistant Human Immunodeficiency Virus Type 1 Strains with Unique Patterns of pol Gene Mutations", <i>J Infect Disease</i> 169:722-729
A93	Shi, <i>et al.</i> , "A Recombinant Retroviral System for Rapid In Vivo Analysis of Human Immunodeficiency Virus Type 1 Susceptibility to reverse Transcriptase Inhibitors", <i>Antimicrobial Agents and Chemotherapy</i> (1997) 41(12): 2781-85.
A94	Shirasaka T, <i>et al.</i> (1995) "Emergence of Human Immunodeficiency Virus Type 1 Variants with Resistance to Multiple Deoxynucleosides in Patients Receiving Therapy with Dideoxynucleosides", <i>PNAS</i> 92:2398-2402
A95	Southern, <i>et al.</i> (1982) "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter", <i>Appl. Genet</i> 1:327-341
A96	Strair RK, <i>et al.</i> (1993) "Recombinant Retroviral Systems For the Analysis of Drug Resistant HIV" <i>Nucl Acids Res</i> , 21(20): 4836-4842
A97	Sugden B, <i>et al.</i> (1985)"A Vector that Replicates as a Plasmid and can be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus", <i>Mol Cell Bio</i> 5:410-413.
A98	Tisdale M, <i>et al.</i> (1993) "Rapid In Vitro Selection of Human Immunodeficiency Virus Type 1 Resistant to 3'-Thiacytidine Inhibitors due to a Mutation in the YMDD Region of Reverse Transcriptase", <i>PNAS</i> 90:5653-5656.
A99	Vacca JP, <i>et al.</i> (1994) "L-735,524: An Orally Bioavailable Human Immunodeficiency Virus Type 1 Protease Inhibitor", <i>PNAS</i> 91:4096-4100.
A100	Villahermosa, ML, <i>et al.</i> "Evaluations of mixtures of wild-type HIV-1 and HIV-1 with resistance point mutations against reverse transcriptase inhibitors" <i>Antiviral Ther.</i> (1998); 3(4):221-227
A101	Zennou V, (1998) "Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo", <i>J. Virol.</i> , 72:3300-3306.
A102	Zhang Y, <i>et al.</i> (1997) "Drug Resistance During Indinavir Therapy is Caused by Mutations in the Protease Gene and in its Gag Substrate Cleavage Sites", <i>J Virol</i> 71:6662-6670.
A103	Zhang D, <i>et al.</i> (1994) "Resistance to 2',3'-Dideoxycytidine Conferred by a Mutation in Codon 65 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase", <i>Antimicrob Agents Chemother</i> 38:282-287

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.